These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 30611165)

  • 1. Insights into complication rates, reoperation rates, and healthcare utilization associated with use of recombinant human bone morphogenetic protein-2 in patients with spine infections.
    Sharma M; Dietz N; Alhourani A; Ugiliweneza B; Wang D; Drazin D; Boakye M
    Neurosurg Focus; 2019 Jan; 46(1):E8. PubMed ID: 30611165
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Usage of recombinant human bone morphogenetic protein in cervical spine procedures: analysis of the MarketScan longitudinal database.
    Cole T; Veeravagu A; Jiang B; Ratliff JK
    J Bone Joint Surg Am; 2014 Sep; 96(17):1409-16. PubMed ID: 25187578
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nationwide practice patterns in the use of recombinant human bone morphogenetic protein-2 in pediatric spine surgery as a function of patient-, hospital-, and procedure-related factors.
    Lam SK; Sayama C; Harris DA; Briceño V; Luerssen TG; Jea A
    J Neurosurg Pediatr; 2014 Nov; 14(5):476-85. PubMed ID: 25171721
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Complications of rhBMP-2 utilization for posterolateral lumbar fusions requiring reoperation: a single practice, retrospective case series report.
    Hoffmann MF; Jones CB; Sietsema DL
    Spine J; 2013 Oct; 13(10):1244-52. PubMed ID: 23973099
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recombinant Human Bone Morphogenetic Protein-2 Use in Adult Spinal Deformity Surgery: Comparative Analysis and Healthcare Utilization at 24 Months' Follow-up.
    Dietz N; Sharma M; Kelly M; Ugiliweneza B; Wang D; Osorio J; Karikari I; Drazin D; Boakye M
    Global Spine J; 2022 Jan; 12(1):92-101. PubMed ID: 32844671
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The efficacy of routine use of recombinant human bone morphogenetic protein-2 in occipitocervical and atlantoaxial fusions of the pediatric spine: a minimum of 12 months' follow-up with computed tomography.
    Sayama C; Hadley C; Monaco GN; Sen A; Brayton A; Briceño V; Tran BH; Ryan SL; Luerssen TG; Fulkerson D; Jea A
    J Neurosurg Pediatr; 2015 Jul; 16(1):14-20. PubMed ID: 25860982
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A large database study of hospitalization charges and follow-up re-admissions in US lumbar fusion surgeries using a cellular bone allograft (CBA) versus recombinant human bone morphogenetic protein-2 (rhBMP-2).
    Wetzell B; McLean JB; Moore MA; Kondragunta V; Dorsch K
    J Orthop Surg Res; 2020 Nov; 15(1):544. PubMed ID: 33213484
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Factors Impacting Outcomes and Health Care Utilization in Osteoporotic Patients Undergoing Lumbar Spine Fusions: A MarketScan Database Analysis.
    Sharma M; John K; Dietz N; Aljuboori Z; Madrigal FC; Adams S; Wang D; Ugiliweneza B; Drazin D; Boakye M
    World Neurosurg; 2020 Sep; 141():e976-e988. PubMed ID: 32585375
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical sequelae after rhBMP-2 use in a minimally invasive transforaminal lumbar interbody fusion.
    Singh K; Nandyala SV; Marquez-Lara A; Cha TD; Khan SN; Fineberg SJ; Pelton MA
    Spine J; 2013 Sep; 13(9):1118-25. PubMed ID: 24029138
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of transforaminal lumbar interbody fusion outcomes in patients receiving rhBMP-2 versus autograft.
    Khan TR; Pearce KR; McAnany SJ; Peters CM; Gupta MC; Zebala LP
    Spine J; 2018 Mar; 18(3):439-446. PubMed ID: 28822825
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A population-based review of bone morphogenetic protein: associated complication and reoperation rates after lumbar spinal fusion.
    Savage JW; Kelly MP; Ellison SA; Anderson PA
    Neurosurg Focus; 2015 Oct; 39(4):E13. PubMed ID: 26424337
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bone morphogenetic protein use in spine surgery in the United States: how have we responded to the warnings?
    Guzman JZ; Merrill RK; Kim JS; Overley SC; Dowdell JE; Somani S; Hecht AC; Cho SK; Qureshi SA
    Spine J; 2017 Sep; 17(9):1247-1254. PubMed ID: 28456674
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Use of recombinant human bone morphogenetic protein-2 to achieve posterolateral lumbar spine fusion in humans: a prospective, randomized clinical pilot trial: 2002 Volvo Award in clinical studies.
    Boden SD; Kang J; Sandhu H; Heller JG
    Spine (Phila Pa 1976); 2002 Dec; 27(23):2662-73. PubMed ID: 12461392
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dose Adjustment Associated Complications of Bone Morphogenetic Protein: A Longitudinal Assessment.
    De Stefano FA; Elarjani T; Burks JD; Burks SS; Levi AD
    World Neurosurg; 2021 Dec; 156():e64-e71. PubMed ID: 34530148
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Corpectomy followed by the placement of instrumentation with titanium cages and recombinant human bone morphogenetic protein-2 for vertebral osteomyelitis.
    Aryan HE; Lu DC; Acosta FL; Ames CP
    J Neurosurg Spine; 2007 Jan; 6(1):23-30. PubMed ID: 17233287
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recombinant human Bone Morphogenetic Protein-2 (rhBMP-2) in posterolateral lumbar spine fusion: complications in the elderly.
    Hoffmann MF; Jones CB; Sietsema DL
    J Orthop Surg Res; 2013 Jan; 8():1. PubMed ID: 23317417
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-Segment Fusion for Adult Spinal Deformity Correction Using Low-Dose Recombinant Human Bone Morphogenetic Protein-2: A Retrospective Review of Fusion Rates.
    Schmitt PJ; Kelleher JP; Ailon T; Heller JE; Kasliwal MK; Shaffrey CI; Smith JS
    Neurosurgery; 2016 Aug; 79(2):212-21. PubMed ID: 26702838
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Counting the Cost of Failed Spinal Fusion for Relief of Low Back Pain: Does Primary Fusion With Bone Morphogenetic Protein Make Economic Sense From a Primary Payer Perspective?
    Lloyd AP
    Clin Spine Surg; 2017 Jul; 30(6):E720-E724. PubMed ID: 28632559
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Longer follow-up continues to reveal no increased risk of cancer with the use of recombinant human bone morphogenetic protein in spine fusion.
    Dettori JR; Chapman JR; DeVine JG; McGuire RA; Junge MR; Norvell DC
    Spine J; 2019 Oct; 19(10):1640-1647. PubMed ID: 31108234
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nerve injury and recovery after lateral lumbar interbody fusion with and without bone morphogenetic protein-2 augmentation: a cohort-controlled study.
    Lykissas MG; Aichmair A; Sama AA; Hughes AP; Lebl DR; Cammisa FP; Girardi FP
    Spine J; 2014 Feb; 14(2):217-24. PubMed ID: 24269858
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.